CL2022002064A1 - Una combinación farmacéutica para el tratamiento de un cáncer - Google Patents
Una combinación farmacéutica para el tratamiento de un cáncerInfo
- Publication number
- CL2022002064A1 CL2022002064A1 CL2022002064A CL2022002064A CL2022002064A1 CL 2022002064 A1 CL2022002064 A1 CL 2022002064A1 CL 2022002064 A CL2022002064 A CL 2022002064A CL 2022002064 A CL2022002064 A CL 2022002064A CL 2022002064 A1 CL2022002064 A1 CL 2022002064A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- cancer
- pharmaceutical combination
- abtl0812
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso de ABTL0812 en el tratamiento de un cáncer en un paciente humano, en donde el tratamiento del cáncer se relaciona con quimioterapia, tratamiento de terapia dirigida, tratamiento de inmunoterapia o tratamiento con radioterapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20382089 | 2020-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002064A1 true CL2022002064A1 (es) | 2023-02-03 |
Family
ID=69770809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002064A CL2022002064A1 (es) | 2020-02-10 | 2022-08-01 | Una combinación farmacéutica para el tratamiento de un cáncer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230088704A1 (es) |
EP (1) | EP4103170A1 (es) |
JP (1) | JP2023514036A (es) |
KR (1) | KR20220140723A (es) |
CN (1) | CN114980879A (es) |
AU (1) | AU2021220258A1 (es) |
BR (1) | BR112022014074A2 (es) |
CA (1) | CA3163864A1 (es) |
CL (1) | CL2022002064A1 (es) |
IL (1) | IL295067A (es) |
MX (1) | MX2022008623A (es) |
TW (1) | TW202139992A (es) |
WO (1) | WO2021160650A1 (es) |
ZA (1) | ZA202207243B (es) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
CA3063625A1 (en) | 2017-05-16 | 2018-11-22 | Ability Pharmaceuticals S.L. | A pharmaceutical combination for the treatment of a cancer |
-
2021
- 2021-02-10 CN CN202180009574.3A patent/CN114980879A/zh active Pending
- 2021-02-10 US US17/798,747 patent/US20230088704A1/en active Pending
- 2021-02-10 IL IL295067A patent/IL295067A/en unknown
- 2021-02-10 AU AU2021220258A patent/AU2021220258A1/en active Pending
- 2021-02-10 BR BR112022014074A patent/BR112022014074A2/pt unknown
- 2021-02-10 MX MX2022008623A patent/MX2022008623A/es unknown
- 2021-02-10 EP EP21704272.0A patent/EP4103170A1/en active Pending
- 2021-02-10 KR KR1020227027110A patent/KR20220140723A/ko unknown
- 2021-02-10 CA CA3163864A patent/CA3163864A1/en active Pending
- 2021-02-10 JP JP2022541844A patent/JP2023514036A/ja active Pending
- 2021-02-10 WO PCT/EP2021/053162 patent/WO2021160650A1/en active Search and Examination
- 2021-02-17 TW TW110105357A patent/TW202139992A/zh unknown
-
2022
- 2022-06-29 ZA ZA2022/07243A patent/ZA202207243B/en unknown
- 2022-08-01 CL CL2022002064A patent/CL2022002064A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112022014074A2 (pt) | 2022-09-13 |
WO2021160650A1 (en) | 2021-08-19 |
ZA202207243B (en) | 2023-03-29 |
EP4103170A1 (en) | 2022-12-21 |
JP2023514036A (ja) | 2023-04-05 |
MX2022008623A (es) | 2022-08-08 |
AU2021220258A1 (en) | 2022-06-30 |
TW202139992A (zh) | 2021-11-01 |
CN114980879A (zh) | 2022-08-30 |
CA3163864A1 (en) | 2021-08-19 |
IL295067A (en) | 2022-09-01 |
KR20220140723A (ko) | 2022-10-18 |
US20230088704A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009773A (es) | Terapia de combinacion. | |
TWD196868S (zh) | 超音波治療手持件 | |
CR20190376A (es) | Formulaciones de anticuerpos de her2 subcutáneas | |
MX2020001727A (es) | Terapia de combinacion. | |
EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
CO2019003865A2 (es) | Proteína terapéutica | |
SV2017005400A (es) | Tratamientos mã‰dicos a base de anamorelina | |
CL2020001888A1 (es) | Terapia de combinación para tratar o prevenir el cáncer. | |
MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
EA201591902A1 (ru) | Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
CL2020002637A1 (es) | Métodos de tratamiento de cáncer. | |
CL2022002064A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer | |
EA202091743A1 (ru) | Вакцинация дендритными клетками параллельно с химиотерапией | |
EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
MX2021001764A (es) | Terapia de combinacion. | |
EA202190294A1 (ru) | Комбинированная терапия для лечения рака |